NCT02685462View on ClinicalTrials.gov

Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 31, 2016

Primary Completion Date

February 23, 2016

Study Completion Date

February 23, 2016

Conditions
Healthy
Interventions
DRUG

Rosuvastatin

DRUG

Atorvastatin

DRUG

Simvastatin

DRUG

Digoxin

DRUG

Caffeine

Trial Locations (1)

Unknown

Miami

All Listed Sponsors
lead

Tobira Therapeutics, Inc.

INDUSTRY

NCT02685462 - Pharmacokinetic and Safety Study of Cenicriviroc and HMG-CoA Reductase Inhibitors, Caffeine and Digoxin | Biotech Hunter | Biotech Hunter